Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2018—LGC Maine Standards has released its Validate Body Fluids kit, 205bf. The kit, in a simulated body fluid matrix, will assist in the documentation of linearity, calibration verification, and verification of the reportable range for albumin, amylase, cholesterol, creatinine, glucose, lactate, lactate dehydrogenase, total protein 2, triglycerides, and urea nitrogen.
December 2018—Agena Bioscience released its Chimeric ID Panel, designed to reduce the time and cost of performing chimerism analysis for bone marrow engraftment monitoring studies.
December 2018—Qiagen announced the worldwide launch of the QIAamp PowerFecal Pro DNA Kit, for the extraction of high-quality DNA from fecal and gut samples.
December 2018—A prospective study in patients with advanced non-small cell lung cancer has demonstrated that the blood-based Guardant360 assay, developed by Guardant Health, identified clinically actionable mutations in nearly twice as many patients as tissue biopsy alone.
December 2018—Australian health care company Primary Health Care has joined forces with Siemens Healthineers to deploy more than 70 Atellica Solution immunoassay and clinical chemistry analyzers.
December 2018—MDxHealth announced that the journal Urology Practice has published a study demonstrating the clinical utility of SelectMDx, a noninvasive liquid biopsy test to identify patients at increased risk of aggressive prostate cancer, in guiding initial prostate biopsy decision-making.
December 2018—LGC Maine Standards released its Validate CM2 linearity and calibration verification kit for Ortho Vitros analyzers.
December 2018—Magnolia Medical Technologies launched its new Best Practice Blood Culture Kit. The kit, developed in partnership with Aero-Med, includes the Steripath Gen2 Initial Specimen Diversion Device, two blood culture bottles, one ChloraSep antiseptic skin prep, and two alcohol prep pads.
December 2018—Qiagen launched its QIAseq FastSelect RNA Removal Kit, which allows rapid selective removal of RNA classes from any sample, enabling researchers to attain high-quality, reproducible RNA sequencing results.
December 2018—Precipio launched a new ICEme kit using the company’s proprietary Ice-Cold PCR technology. The kit provides physicians with the ability to use a liquid biopsy to identify patients eligible for tyrosine kinase inhibitor therapies through analysis of tumor DNA for these EGFR mutations.
